Ocuphire Pharma Inc expected to post a loss of 22 cents a share - Earnings Preview

Opus Genetics

31/10/2023 11:12

* Ocuphire Pharma Inc  OCUP.OQ   OCUP.O  is expected to show
a
rise in quarterly revenue when it reports  results 
    * The Farmington Hills Michigan-based  company is expected
to
report revenue of $3.025 million, according to the mean estimate
from 5 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Ocuphire Pharma Inc
is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ocuphire
Pharma
Inc is $20​, above​ its last closing price of $2.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.25       -0.23      -0.24     Missed  -6.2
 Mar. 31 2023  -0.18       -0.15      -0.28     Missed  -81.8
 Dec. 31 2022              0.97       1.58      Beat    63.3​
 Sep. 30 2022  -0.29       -0.29      -0.22     Beat    23.7
 ​​Jun.        -0.33       -0.33      -0.25     Beat    24.7
 30 2022                                                
 Mar. 31 2022  -0.34       -0.35      -0.35     Met     0​
 Dec. 31 2021  -0.20       -0.29      -0.35     Missed  -22.1
 Sep. 30 2021  -0.39       -0.36      -0.25     Beat    30.2
 This summary was machine generated October 31 at 11:12 GMT.  All
figures in US dollars  unless otherwise stated